U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951086) titled 'A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis' on Nov. 16.

Brief Summary: The purpose of this Phase 2 study is:

1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA).

2. to provide information about dose selection and study design for subsequent clinical development.

Study Start Date: Jan. 26, 2027

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis

Intervention: DRUG: DDY391

DDY391

DRUG: Placebo

Matching placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Ph...